The purpose of this study is to evaluate the safety and effectiveness of the drug bortezomib in never-smokers with non-small cell lung cancer (NSCLC) that contains a mutation in the KRAS gene. Former or current smokers with NSCLC that contains a specific mutation called KRAS G12D may also participate.
Bortezomib is approved for treating multiple myeloma and mantle cell lymphoma, but its use in this study is considered investigational. Research suggests that certain patients with KRAS-mutant lung cancer may benefit from bortezomib therapy as well. Bortezomib works by inhibiting many proteins (known as proteasomes) that cancer cells need to survive and multiply.